Articles with keyword CTLA-4
-
Immuno-related adverse events of checkpoint inhibitors
G.Yu. Kharkevich, K.V. Orlova
immune-related adverse events, skin toxicity, colitis, hepatitis,anti-CTLA-4, anti-PD-1, hypophysitis, melanoma
-
Biomarkers predicting the effect of immunotherapy: what you need to know in practice?
A.M. Konstantinova
immunotherapy, CTLA-4, PD-1, PD-L1, microsatellite instability, mutation burden, tumor-infiltrating lymphocytes, biomarkers, efficacy.
-
Efficacy of immune checkpoints inhibitors in the treatment of solid tumors
A.A. Rumyantsev, S.A. Tjulandin
drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy